Clinical Trials Logo

Filter by:
NCT ID: NCT05048134 Recruiting - Clinical trials for Advanced Malignancies

A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies

Start date: October 25, 2021
Phase: Phase 1
Study type: Interventional

The study is being conducted to evaluate the safety and tolerability of HRS2300 and combined with SHR-1316 or SHR-1701 or trametinib or Almonertinib.To Determine the maximum tolerated dose (MTD) and recommended Dose (RP2D) for HRS2300 monotherapy and combination therapy.

NCT ID: NCT05048017 Recruiting - Clinical trials for Hepatocellular Carcinoma

Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma

Start date: October 1, 2021
Phase: Phase 2
Study type: Interventional

This is a single arm, nonrandomized, single center clinical study to investigate the safety and efficacy of regorafenib combined with PD-1 inhibitor therapy for second-line treatment of hepatocellular carcinoma

NCT ID: NCT05047848 Recruiting - Clinical trials for Advanced Breast Cancer

Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer

Start date: August 18, 2021
Phase: N/A
Study type: Interventional

This is a Open-label study of chidamide in combination with fulvestrant for the treatment of postmenopausal women with hormone receptor positive, Her2 negative, advanced breast cancer who have received no or only one line of endocrine therapy for advanced breast cancer.

NCT ID: NCT05047510 Recruiting - Clinical trials for Hepatocellular Carcinoma

GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma

Start date: September 10, 2021
Phase: N/A
Study type: Interventional

This study is to evaluate whether intraoperative fluorescence imaging targeting GPC3 can aid improve the surgical accuracy of hepatocellular carcinoma. The main purposes of this study include: ① To raise the detection rate of hepatocellular carcinoma intraoperatively using the novel NIR-II fluorescence molecular imaging and the GPC-3 targeted fluorophore. ② To validate the safety and effectiveness of the designed GPC-3 targeted fluorophore for clinical application.

NCT ID: NCT05047250 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

Start date: June 14, 2022
Phase: Phase 3
Study type: Interventional

This is a Phase III, single arm, multicenter study designed to evaluate the efficacy and safety of atezolizumab in high PD-L1 expression, chemotherapy-naïve, without a sensitizing EGFR mutation or ALK translocation patients with stage IV non-squamous or squamous NSCLC.

NCT ID: NCT05046847 Recruiting - Solid Tumor Clinical Trials

A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3811 Tablets in Patients With Advanced Malignant Tumors

Start date: November 30, 2021
Phase: Phase 1
Study type: Interventional

TQB3811 tablet is a second-generation tropomyosin receptor kinase (TRK) inhibitor that selectively inhibits the kinase activity of TRKA, TRKB, and TRKC, and also selectively inhibits the kinase activity of TRKA, TRKB, and TRKC that produce secondary drug-resistant mutations.

NCT ID: NCT05046366 Recruiting - Lung Cancer Clinical Trials

Development of an Artificial Intelligence System for Intelligent Pathological Diagnosis and Therapeutic Effect Prediction Based on Multimodal Data Fusion of Common Tumors and Major Infectious Diseases in the Respiratory System Using Deep Learning Technology.

Start date: October 1, 2021
Phase:
Study type: Observational

To improve accurate diagnosis and treatment of common malignant tumors and major infectious diseases in the respiratory system, we aim to establish a large medical database that includes standardized and structured clinical diagnosis and treatment information such as electronic medical records, image features, pathological features, and multi-omics information, and to develop a multi-modal data fusion-based technology system for individualized intelligent pathological diagnosis and therapeutic effect prediction using artificial intelligence technology.

NCT ID: NCT05046314 Recruiting - Sarcoma, Ewing Clinical Trials

A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma

Start date: March 12, 2024
Phase: Phase 2
Study type: Interventional

This study is a multicenter, single-arm, open-label Phase II clinical trial evaluating TK216 in combination with vincristine in the treatment of relapsed or refractory Ewing sarcoma (ES) including Ewing's sarcoma family tumors (ESFTs).

NCT ID: NCT05045911 Recruiting - Clinical trials for Colorectal Neoplasms

An Endoscopic Barbed-clips Suturing for Colorectal ESD

Start date: September 20, 2021
Phase: N/A
Study type: Interventional

Endoscopic submucosal dissection (ESD) was developed to allow en bloc resection of colorectal neoplasm. Although colorectal ESD has been widely accepted as a minimally invasive treatment option for early colorectal neoplasm, post-ESD bleeding is one of the major adverse events. After ESD procedure, endoscopists close the defects with devices to prevent complications. A novel endoscopic barbed-clips suturing has been developed to simplify endoscopic closure. In this study, the endoscopic barbed-clips will be evaluated when closing defects in the colon after ESD.

NCT ID: NCT05045872 Recruiting - Clinical trials for Chronic Kidney Diseases

Assessment of Renal Vasculature and Function With Ferumoxytol-enhanced Magnetic Resonance Imaging

Start date: September 17, 2021
Phase: Phase 1
Study type: Interventional

Conventional contrast-enhanced magnetic resonance imaging is typically performed with extracellular gadolinium chelates, which is often limited in patients with CKD owing to the risk of nephrogenic systemic fibrosis. Ferumoxytol, a novel contrast medium, can be used as an "off-label" contrast agent for magnetic resonance imaging. During the last decade, ferumoxytol has gained appeal as an MRI contrast agent in patients with estimated glomerular filtration rates <30mL/min and there are reports in the literature for its safe use and utility in both adult and pediatric patients with CKD. The study is designed to evaluate the diagnostic performance of ferumoxytol-enhanced magnetic resonance imaging in patients suspected of renal artery stenosis, investigate the correlation between renal cortical T2*(T2*=1/R2*) and renal function, and develop an automatic algorithms for renal vessel segmentation.